Health Care [ 11/12 ] | Health Care Equipment & Supplies [ 59/74 ]
NASDAQ | Common Stock
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs.
The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.05 Increased by +44.44% | -0.06 Increased by +21.01% |
| Nov 11, 24 | -0.06 Decreased by -15.00% | -0.06 Increased by +4.17% |
| Aug 12, 24 | -0.05 Increased by +37.50% | -0.06 Increased by +16.67% |
| May 13, 24 | -0.05 Increased by 0.00% | -0.07 Increased by +28.57% |
| Mar 28, 24 | -0.09 Decreased by -50.00% | -0.06 Decreased by -50.00% |
| Nov 13, 23 | -0.05 Increased by +16.67% | -0.07 Increased by +28.57% |
| Aug 14, 23 | -0.08 Decreased by -60.00% | -0.06 Decreased by -33.33% |
| May 15, 23 | -0.05 Decreased by -25.00% | -0.06 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -6.35 M Increased by +18.15% | Decreased by N/A% - |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.23 M Decreased by -16.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.05 M Increased by +38.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 18.00 K Increased by +N/A% | -5.88 M Decreased by -7.64% | Decreased by -32.66 K% Decreased by N/A% |
| Dec 31, 23 | N/A Decreased by N/A% | -7.75 M Decreased by -13.30% | - - |
| Sep 30, 23 | 0.00 Decreased by N/A% | -6.23 M Increased by +20.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.83 M Decreased by -45.65% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.46 M Decreased by -13.18% | Decreased by N/A% Decreased by N/A% |